Insights into Company

Emami ↗

1974 📍 Kolkata, West Bengal, India Active NSE EMAMILTD CIN L63993WB1983PLC036030 FMCG - Personal & Home Care
Search companies

Key Metrics of Emami

Revenue₹3,048 Cr▼ 2.4% YoYFY 2025-26
EBITDA₹1,058 Cr▼ 3.3% YoY
Net profit₹842 Cr▼ 2.0% YoY
Net worth₹3,156 Cr▲ 10.1% YoY
Competitors10identified

About Emami

Sectors

FMCG - Personal & Home CareShampoo, Hair Oil & Hair CareBanking & Financial ServicesFintech, Broking & Market Infrastructure

Company details

Website
emamiltd.in
Founded
1974
Registered office
687 Anandapur ,e.m. Bypass, Kolkata, West Bengal, India,, Kolkata, In-wb, 700107
Listed
NSE: EMAMILTD · ₹373.15

Operational Areas of Emami

FMCG - Personal & Home Care›Shampoo, Hair Oil & Hair Care
Banking & Financial Services›Fintech, Broking & Market Infrastructure

Company summary

Entity details

CINL63993WB1983PLC036030
LEI code335800CCQHJCDEUS7G90
State codeWB
PIN code700107
Current legal nameEMAMI
Classification—
Listing statusListed (NSE: EMAMILTD)
Registration no.036030
Company age52 years, 9 months
PAN—
CountryIndia
CityKolkata
StateWest Bengal
Current statusActive
Date of incorporation01 Jan 1974
Registrar of companies—
Authorised capital—
Paid-up capital—
Employee count—

Compliance

Last AGM date—
Last balance sheet—
Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026

Industry classification

NIC code63993
Description of main activitySupporting transport activities; travel agencies
Description of business activitySupporting transport activities; travel agencies
SectorFMCG - Personal & Home Care · Shampoo, Hair Oil & Hair Care
Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Sign in to continue See plans & pricing

Filing compliance

AGM for FY 2025-2630 Sep 2026 Statutory due date passed
AOC-4 for FY 2025-2630 Oct 2026 Statutory due date · 4 days left
MGT-7 for FY 2025-2629 Nov 2026 Statutory due date · 34 days left

Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.

Vendor checks & payment capacity

Sign in with access to company financials to review vendor evidence.

Credit ratings

CARE · 17 Dec 2025 CARE AA+ Stable outlook · Short term A1+ · Reaffirmed
Change in last 12 monthsNo change
Change since first rating on recordNo changesince Aug 2019
Rating actions80 up · 0 down
Liquidity (CARE)Strong

Rating history

Rating actions

DateAgencyActionLong termShort termOutlookRated amountRationale
17 Dec 2025CAREReaffirmed AA+A1+Stable₹168 Cr View
19 Sep 2024CAREReaffirmed AA+A1+Stable₹368 Cr View
03 Oct 2023CAREReaffirmed AA+A1+Stable₹368 Cr View
22 Sep 2022CAREOther ———— View
23 Sep 2021CAREReaffirmed AA+A1+Stable₹153 Cr View
24 Sep 2020CAREReaffirmed AA+A1+Stable₹653 Cr View
18 Aug 2020CAREOther ———— View
19 Aug 2019CAREReaffirmed AA+A1+Negative₹670 Cr View

Credit strengths (CARE, Dec 2025)

+ Long and established track record of operations in the FMCG industry

EL was established in 1974 as Kemco Chemicals, manufacturing cosmetic products and ayurvedic medicines under the brand ‘Emami’. In 1978, promoters acquired Himani Limited, expanding into cosmetics. Over time, EL diversified through new launches and acquisitions, including Zandu, Keshking, Crème 21, and Dermicool. In FY21, EL entered the hygiene segment with Boroplus hand sanitizers and antiseptic soap to capture growing demand.

+ Established brands in ayurvedic/herbal personal care segments with strong market share in few of them

EL markets over 500 ayurvedic, herbal, cosmetic, and health care products through 5.4 million retail outlets in India and in over 70 countries globally. Brands including Boroplus, Navratna, Dermicool, Zandu, Mentho Plus Balm, Fair and Handsome, and Kesh King hold significant market share and are expected to contribute strongly to revenue. Revenue from Navratna, Dermicool, Boroplus, Zandu range grew in FY25, while that from Kesh King, Fair and Handsome, The Man Co. & Brillare declined. EL underto

+ Regular investment in brand strengthening and inorganic growth focussed on D2C

Advertisement and sales promotion expenses were 18.28% of sales in FY25, broadly in line with 18.4% in FY24. CareEdge Ratings notes that EL is gradually expanding its presence in e-commerce channels to capture growing online demand. Over the years, EL increased its strategic stakes in Helios Lifestyle (male grooming brand “The Man Company”) and Brillare Science (skin/hair care), where it currently holds 100% equity stake. In July 2022, EL acquired 30% stake in Cannis Lupus Services (pet

+ Wide marketing and distribution channel

EL has three distinct marketing channels, including retail, rural trade and export. Retail sales take place through 3, 400 distributors and 26 distribution centres . The company has direct and indirect coverage through ~54 lakh retailers in FY25. EL also has presence in the overseas market (17.10% of consolidated sales in FY25), apart from established domestic presence. EL has 26 depots across India. Products are also sold through organised retail chains and e-commerce platforms. Institutional s

+ Robust financial performance in FY25, however witnessed moderation in H1FY26

The company’s overall performance improved in FY25 compared to FY24 with revenue growing by 6% y-o-y. Growth in revenue was driven by growth in domestic business by 7%, international business by ~4%. The PBILDT margin remained healthy and above industry average at 26.69% in FY25, considering better cost management across all functions. ROCE and return on net worth (RONW) also remained comfortable in FY25. The company has been distributing high

+ Robust capital structure and debt coverage indicators

The company’s capital structure and debt coverage indicators remained robust with minimal total debt. Overall gearing stood at 0.03x as on March 31, 2025 (0.04x as on March 31, 2024) and TD/gross cash accruals (GCA) stood at 0.10x as on March 31, 2025 (PY: 0.11x). Working capital limit utilisation stood at negligible levels for 12 months ended November 2025. With no major debt funded capex/acquisition plans in the medium term and healthy liquidity, CareEdge Ratings expects capital structure to

Credit challenges

− Susceptibility of its profitability to volatility in raw material prices

Key raw materials for EL include menthol, packaging materials, and vegetable oils. Polymer prices, used in packaging, are linked to crude oil prices, which are volatile. Menthol oil, light liquid paraffin (LLP), rice bran oil (RBO), seshale wax, and sesame (til) oil are key raw materials for healthcare and personal care products. Most raw materials are sourced domestically, with limited imports. Due to intense competition and price-sensitive consumers, EL may face challenges in passing on raw ma

− Intense competition in FMCG industry

The Indian FMCG market is highly competitive, with numerous organised and unorganised players offering similar products. High competition necessitates increased advertising and promotional spending. Large domestic players and multinational corporations (MNCs) enjoy price and quality advantages over smaller competitors. The market remains fragmented, with rural consumers using unbranded products, creating competition from small and medium manufacturers. Despite fragmentation, low penetration leve

Could lead to an upgrade

• Substantial growth in its scale of operations (TOI and tangible net worth [TNW]) along with revenue diversification across various product categories and thereby gaining significant market share in the overall FMCG industry • Maintaining significant free

Could lead to a downgrade

• Moderation in its return on capital employed (ROCE) to below 20% on a sustained basis. • Overall gearing and total debt to profit before interest, lease rentals, depreciation and taxation (TD/PBILDT)of over 0.50x on a sustained basis. • Material increase in the percentage of pledge of the promoters’ share in EL from the existing levels.

Agency-reported financials (CARE, 17 Dec 2025)

MetricH1FY26
Total operating income₹1,703 Cr
PBILDT*₹389 Cr
PAT₹313 Cr
Overall gearing (times)0.03×
Interest coverage (times)76.84×
PAT margin18.4%

Borrowings & rated debt

Rated borrowing limits (latest)₹168 Cr
Peak rated limits₹670 CrAug 2019 · CARE
Limits raised0 times0 new facilities rated

Rated limits over time

Facility mix

Rated facilities

FacilityTypePreviousCurrentChangeRatingActionAgency
Long-term Short-term bank facilitiesWorking capital & bank lines—₹168 Cr— AA+ / A1+ (Stable)ReaffirmedCARE

CARE ratings on record (checked 24 Oct 2026)

InstrumentAmountRating
Commercial Paper (Standalone)—Withdrawn
LT/ST₹168 CrCARE AA+; Stable / CARE A1+
Non Convertible Debentures—Withdrawn

Lenders

Fund-based/Non-fund-basedLT/STCiti Bank
Fund-based/Non-fund-basedLT/STDBS Bank India Ltd.
Fund-based/Non-fund-basedLT/STHDFC Bank Ltd.
Fund-based/Non-fund-basedLT/STHSBC Ltd.
Fund-based/Non-fund-basedLT/STICICI Bank Ltd.
Fund-based/Non-fund-basedLT/STStandard Chartered Bank

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26

Indicative long-term—
Indicative short-term—
Score—
LiquidityStrong
DirectionStable

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

DefaultNo default on record
Issuer cooperationCooperating
Credit enhancementNone – standalone rating
Information on file56% · missing: Capex / investment plans, Lender details, Auditor details, Recent rating review (last 15 months)

Indicative assessment from public data using the published methodology factors; not a credit rating.

Borrowing & funding lifecycle

⬇ PDF report⬇ Excel
Can it borrow more?Further bank funding likely Next rating action stable or better: 83% (Stable or improving) · ML model on 4072 rating histories, AUC 0.666
Rated limits₹168 Cr
Not yet allocated—
Extra debt within 3.5× EBITDA—
Interest coverage76.84×
Limit utilisation—
Open bank charges0 · —
  • Credit outlook model: 83% chance the next rating action is stable or better
  • Current rating AA+ (investment grade)
  • Interest coverage 76.84×

Rated limits by facility

Timeline

17 Dec 2025 CARE reaffirmed: AA+ (Stable)Rated limits ₹168 cr CARE rationale
19 Sep 2024 CARE reaffirmed: AA+ (Stable)Rated limits ₹368 cr CARE rationale
19 Sep 2024 Cash & liquid funds ₹638 cr
From the report

Press Release Liquidity: Strong The company’s liquidity is marked by strong accruals in FY24 and Q1FY25 against nil term debt repayment obligations and cash and bank balance of ₹638 crore as on June 30, 2024 (consolidated).

CARE rationale
19 Sep 2024 Average working-capital utilisation 10%
From the report

Average working capital limit utilisation also remained low at less than 10% for the last 12 months ended June 30, 2024.

CARE rationale
03 Oct 2023 CARE reaffirmed: AA+ (Stable)Rated limits ₹368 cr CARE rationale
03 Oct 2023 Cash & liquid funds ₹308 cr
From the report

Liquidity: Strong The liquidity of the company is marked by strong accruals in FY23 and Q1FY24 against nil debt repayment obligations and cash and bank balance of ₹308 crore as on June 30, 2023 (consolidated).

CARE rationale
03 Oct 2023 Average working-capital utilisation 4.62%
From the report

The average working capital utilisation also remained low at 4.62% for the last 12 months ended June 2023.

CARE rationale
22 Sep 2022 CARE other: — CARE rationale
22 Sep 2022 Cash & liquid funds ₹887 cr
From the report

The company earned healthy gross cash accruals (GCA) of ₹887 crore in FY22.

CARE rationale
22 Sep 2022 Cash & liquid funds ₹214 cr
From the report

Liquidity: Strong EL’s liquidity is marked by strong accruals in FY22 and Q1FY23 against nil long-term debt repayment obligations along with cash and bank balance and liquid investments of Rs.214 crore as on June 30, 2022 (consolidated).

CARE rationale
22 Sep 2022 Average working-capital utilisation 23%
From the report

The average working capital utilisation also remained comfortable at 23% for the trailing 12 months ended July 2022.

CARE rationale
23 Sep 2021 CARE reaffirmed: AA+ (Stable)Rated limits ₹153 cr CARE rationale
23 Sep 2021 Cash & liquid funds ₹529 cr
From the report

Liquidity: Strong EL’s liquidity is marked by strong accruals in FY21 and Q1FY22 against nil long-term debt repayment obligations along with cash and bank balance of Rs.529 crore as on June 30, 2021 (consolidated).

CARE rationale
23 Sep 2021 Average working-capital utilisation 42%
From the report

The average working capital utilisation also remained comfortable at 42% for the trailing 12 months ended June 30, 2021.

CARE rationale
24 Sep 2020 CARE reaffirmed: AA+ (Stable)Rated limits ₹653 cr CARE rationale
24 Sep 2020 Cash & liquid funds ₹122 cr
From the report

Liquidity: Strong Liquidity is marked by strong accruals in FY20 and Q1FY21 against negligible repayment obligations along with cash and liquid investments to the tune of Rs.122 crore as on March 31, 2020.

CARE rationale
24 Sep 2020 Average working-capital utilisation 34%
From the report

The average working capital limit utilisation also remained comfortable at 34% for 12 months ended June 30, 2020.

CARE rationale
24 Sep 2020 New borrowing arranged: ₹75 cr (term loans)
From the report

However, the company had availed an adhoc limit of Rs.75 crore in March 2020 which has since been repaid.

CARE rationale
18 Aug 2020 CARE other: — CARE rationale
18 Aug 2020 Cash & liquid funds ₹187 cr
From the report

Liquidity: Strong Liquidity is marked by strong accruals against negligible repayment obligations along with cash and liquid investments to the tune of Rs.187 crore as on March 31, 2020 and Rs.131.90 crore as on July 31, 2020.

CARE rationale
19 Aug 2019 CARE reaffirmed: AA+ (Negative)Rated limits ₹670 cr CARE rationale
19 Aug 2019 Cash & liquid funds ₹208 cr
From the report

Liquidity Analysis: Strong The liquidity position is comfortable as evident from cash and bank balance (incl. liquid investments, fixed deposits) of Rs.208 crore in FY19 vis-à-vis Rs.199 crore in FY18.

CARE rationale

Lender names, bank charges and audited borrowings are part of Premium.

Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.

Registered office and contact

Registered office687 ANANDAPUR ,E.M. BYPASS, KOLKATA, WEST BENGAL, INDIA,, KOLKATA, IN-WB, 700107
GSTIN—
Email—
Websitehttps://www.emamiltd.in
Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Competitors of Emami

Competitors10identified
Locations3most in India

Top competitors by location

CompanyDescriptionDomainFoundedLocation
Larsen & Toubro Capital Goods & Power Equipment · Heavy Engineering & Capital Goods larsentoubro.com 1938 Mumbai, India
ITC Limited Part of Life Insurance Corporation of India. itcportal.com 1910 Kolkata, India
ABANS FINANCIAL SERVICES LIMITED Fintech, Broking & Market Infrastructure · Banking & Financial Services — — Mumbai, Maharashtra, India
Dabur India Beverages & Soft Drinks · Food & Beverages dabur.com — New Delhi, India
Arvind Limited Textiles, Cotton & Yarn · Apparel, Textiles & Footwear arvind.com — Ahmedabad, India
Thermax Capital Goods & Power Equipment · Heavy Engineering & Capital Goods thermaxglobal.com 1980 Pune, India
PB FINTECH LIMITED Fintech, Broking & Market Infrastructure · Banking & Financial Services pbfintech.in 2008 Gurgaon, Haryana, India
ANGEL ONE LIMITED Fintech, Broking & Market Infrastructure · Finance angelone.in — Mumbai, Maharashtra, India
NUVAMA WEALTH MANAGEMENT LIMITED Fintech, Broking & Market Infrastructure · Finance nuvamawealth.com — Mumbai, Maharashtra, India
Kirloskar Brothers Capital Goods & Power Equipment · Heavy Engineering & Capital Goods kirloskarpumps.com 1888 Pune, India

Similar companies

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Business activities and related parties

Hair oil, ayurvedic personal care and OTC

Filings

No filings on record yet.